Relationship between tumor response and the gene expression in Gimeracil/oteracil/tegafur or Tegafur-uracil /Leucovorin treated patients with locally advanced rectal cancer

Trial Profile

Relationship between tumor response and the gene expression in Gimeracil/oteracil/tegafur or Tegafur-uracil /Leucovorin treated patients with locally advanced rectal cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Folinic acid (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Tegafur/uracil (Primary)
  • Indications Rectal cancer
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms 15R-153; SN15-011
  • Most Recent Events

    • 01 Jun 2017 Results published in the Cancer Chemotherapy and Pharmacology.
    • 01 Dec 2016 New trial record
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top